|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Razi S, Ghoncheh M, Mohammadian-Hafshejani
A, Aziznejhad H, Mohammadian M and Salehiniya H: The incidence and
mortality of ovarian cancer and their relationship with the Human
Development Index in Asia. Ecancermedicalscience. 10:6282016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Karnezis AN, Cho KR, Gilks CB, Pearce CL
and Huntsman DG: The disparate origins of ovarian cancers:
Pathogenesis and prevention strategies. Nat Rev Cancer. 17:65–74.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Voutsadakis IA: On adjuvant hormone
therapy in epithelial ovarian cancer. J Clin Oncol. 34:2070–2071.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chung C and Lee R: An update on current
and emerging therapies for epithelial ovarian cancer: Focus on poly
(adenosine diphosphate-ribose) polymerase inhibition and
antiangiogenesis. J Oncol Pharm Pract. 23:454–469. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rojas V, Hirshfield KM, Ganesan S and
Rodriguez-Rodriguez L: Molecular characterization of epithelial
ovarian cancer: Implications for diagnosis and treatment. Int J Mol
Sci. 17(pii): E21132016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Harvey KF, Zhang X and Thomas DM: The
Hippo pathway and human cancer. Nat Rev Cancer. 13:246–257. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wierzbicki PM and Rybarczyk A: The Hippo
pathway in colorectal cancer. Folia Histochem Cytobiol. 53:105–119.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ma Y, Yang Y, Wang F, Wei Q and Qin H:
Hippo-YAP signaling pathway: A new paradigm for cancer therapy. Int
J Cancer. 137:2275–2286. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Piccolo S, Dupont S and Cordenonsi M: The
biology of YAP/TAZ: Hippo signaling and beyond. Physiol Rev.
94:1287–1312. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xia Y, Chang T, Wang Y, Liu Y, Li W, Li M
and Fan HY: YAP promotes ovarian cancer cell tumorigenesis and is
indicative of a poor prognosis for ovarian cancer patients. PloS
One. 9:e917702014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cho SY, Kim K, Park MS, Jang MY, Choi YH,
Han S, Shin HM, Chung C, Han HY, Yang JB, et al: Expression of
yes-associated protein 1 and its clinical significance in ovarian
serous cystadenocarcinoma. Oncol Rep. 37:2620–2632. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jeong GO, Shin SH, Seo EJ, Kwon YW, Heo
SC, Kim KH, Yoon MS, Suh DS and Kim JH: TAZ mediates
lysophosphatidic acid-induced migration and proliferation of
epithelial ovarian cancer cells. Cell Physiol Biochem. 32:253–263.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xia Y, Zhang YL, Yu C, Chang T and Fan HY:
YAP/TEAD co-activator regulated pluripotency and chemoresistance in
ovarian cancer initiated cells. PloS One. 9:e1095752014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu M, Xiao J, Chen M, Yuan L, Li J, Shen H
and Yao S: miR1495p promotes chemotherapeutic resistance in ovarian
cancer via the inactivation of the Hippo signaling pathway. Int J
Oncol. 52:815–827. 2018.PubMed/NCBI
|
|
16
|
Yagi H, Asanoma K, Ohgami T, Ichinoe A,
Sonoda K and Kato K: GEP oncogene promotes cell proliferation
through YAP activation in ovarian cancer. Oncogene. 35:4471–4480.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang X, George J, Deb S, Degoutin JL,
Takano EA, Fox SB, Bowtell DD and Harvey KF: The Hippo pathway
transcriptional co-activator, YAP, is an ovarian cancer oncogene.
Oncogene. 30:2810–2822. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lou Y and Liu S: The TIPE (TNFAIP8) family
in inflammation, immunity and cancer. Mol Immunol. 49:4–7. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sun H, Lou Y, Porturas T, Morrissey S, Luo
G, Qi J, Ruan Q, Shi S and Chen YH: Exacerbated experimental
colitis in TNFAIP8-deficient mice. J Immunol. 194:5736–5742. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gao HY, Huo FC, Wang HY and Pei DS:
MicroRNA-9 inhibits the gastric cancer cell proliferation by
targeting TNFAIP8. Cell Prolif. 50:2017. View Article : Google Scholar
|
|
21
|
Lowe JM, Nguyen TA, Grimm SA, Gabor KA,
Peddada SD, Li L, Anderson CW, Resnick MA, Menendez D and Fessler
MB: The novel p53 target TNFAIP8 variant 2 is increased in cancer
and offsets p53-dependent tumor suppression. Cell Death Differ.
24:181–191. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xiao M, Xu Q, Lou C, Qin Y, Ning X, Liu T,
Zhao X, Jia S and Huang Y: Overexpression of TNFAIP8 is associated
with tumor aggressiveness and poor prognosis in patients with
invasive ductal breast carcinoma. Hum Pathol. 62:40–49. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu T, Gao H, Chen X, Lou G, Gu L, Yang M,
Xia B and Yin H: TNFAIP8 as a predictor of metastasis and a novel
prognostic biomarker in patients with epithelial ovarian cancer. Br
J Cancer. 109:1685–1692. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu T, Xia B, Lu Y, Xu Y and Lou G:
TNFAIP8 overexpression is associated with platinum resistance in
epithelial ovarian cancers with optimal cytoreduction. Hum Pathol.
45:1251–1257. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dai L, Cui X, Zhang X, Cheng L, Liu Y,
Yang Y, Fan P, Wang Q, Lin Y, Zhang J, et al: SARI inhibits
angiogenesis and tumour growth of human colon cancer through
directly targeting ceruloplasmin. Nat Commun. 7:119962016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sun Z, Liu X, Song JH, Cheng Y, Liu Y, Jia
Y, Meltzer SJ and Wang Z: TNFAIP8 overexpression: a potential
predictor of lymphatic metastatic recurrence in pN0 esophageal
squamous cell carcinoma after Ivor Lewis esophagectomy. Tumour
Biol. 37:10923–10934. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dong Q, Fu L, Zhao Y, Xie C, Li Q and Wang
E: TNFAIP8 interacts with LATS1 and promotes aggressiveness through
regulation of Hippo pathway in hepatocellular carcinoma.
Oncotarget. 28:15689–15703. 2017.
|
|
29
|
Han Y, Tang Z, Zhao Y Li Q and Wang E:
TNFAIP8 regulates Hippo pathway through interacting with LATS1 to
promote cell proliferation and invasion in lung cancer. Mol
Carcinog. 57:159–166. 2018. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xing B and Ren C: Tumor-suppressive
miR-99a inhibits cell proliferation via targeting of TNFAIP8 in
osteosarcoma cells. Am J Transl Res. 8:1082–1090. 2016.PubMed/NCBI
|
|
31
|
Hall CA, Wang R, Miao J, Oliva E, Shen X,
Wheeler T, Hilsenbeck SG, Orsulic S and Goode S: Hippo pathway
effector Yap is an ovarian cancer oncogene. Cancer Res.
70:8517–8525. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim M and Jho EH: Cross-talk between
Wnt/β-catenin and Hippo signaling pathways: A brief review. BMB
reports. 47:540–545. 2014. View Article : Google Scholar : PubMed/NCBI
|
